Malaria Pregnancy and Childbirth malaria prevention during pregnancy
Conditions
Interventions
SulphadoxinePyrmethamine
Dihydroartemisinin Piperaquine DHA
Sponsors
Federal Teaching Hospital Abakaliki
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1. Pregnant women between 14 weeks and 24 weeks gestation with viable pregnancy. 2. Women who have not received intermittent preventive treatment with sulphadoxine–pyrimethamine during the index pregnancy. 3. Women not allergic to sulphadoxine-pyrimethamine or dihydroartemisinin-piperaquine. 4. Women willing to deliver in the study hospital.
Exclusion criteria
Exclusion criteria: 1. Women in the first trimester of pregnancy. 2. HIV positive pregnant women 3. Women allergic to sulphadoxine-pyrimethamine or dihydroartemisini-piperaquine. 4. Women with high-risk pregnancies e.g. medical diseases in pregnancy (sickle cell disease, diabetes mellitus, hypertensive disorders in pregnancy) and multiple gestations. 5. Women who do not consent to the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| prevalence of placental malaria | — |
Secondary
| Measure | Time frame |
|---|---|
| Incidence of symptomatic malaria, adverse birth outcomes, including spontaneous abortion, stillbirth, low birth weight (<2500 g), and preterm delivery (<37 weeks). | — |
Countries
Nigeria
Contacts
Public ContactChidiebere Anikwe
Obstetrician
Outcome results
None listed